Rapid Implementation of Service Delivery Changes to Mitigate COVID-19 and Maintain Access to Methadone Among Persons with and at High-Risk for HIV in an Opioid Treatment Program

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2020 Apr 30

PMID 32347404

Citations 36

Authors

K Michelle Peavy

James Darnton

Paul Grekin

Monica Russo

Caleb J Banta Green

Joseph O Merrill

Charissa Fotinos

Steve Woolworth

Sean Soth

Judith I Tsui

Affiliations

Soon will be listed here.

Citing Articles

Opioid Treatment Programs and Risks for COVID-19 Infections, Emergency Visits, and Hospitalizations.

Cook R, Blalock K, El Ibrahimi S, Hoffman K, Levander X, Little K J Gen Intern Med. 2025; .

PMID: 40000522 DOI: 10.1007/s11606-025-09444-3.

Methadone clinic staff perceptions of trauma-informed and patient-centered care: the role of individual staff characteristics.

Meyerson B, Linde-Krieger L, Carter G, Huff A, Brady B, Crosby R Addict Sci Clin Pract. 2024; 19(1):87.

PMID: 39616394 PMC: 11608490. DOI: 10.1186/s13722-024-00501-6.

When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?.

El-Sabawi T, Gillespie K AMA J Ethics. 2024; 26(7):E520-526.

PMID: 38958420 PMC: 11293620. DOI: 10.1001/amajethics.2024.520.

Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19.

Meyerson B, Bentele K, Brady B, Stavros N, Russell D, Mahoney A AJPM Focus. 2024; 3(2):100177.

PMID: 38312524 PMC: 10835120. DOI: 10.1016/j.focus.2023.100177.

Improving the quality of counseling and clinical supervision in opioid treatment programs: how can technology help?.

Peavy K, Klipsch A, Soma C, Pace B, Imel Z, Tanana M Addict Sci Clin Pract. 2024; 19(1):8.

PMID: 38245783 PMC: 10799386. DOI: 10.1186/s13722-024-00435-z.

References

Evans M, Labuda S, Hogan V, Agnew-Brune C, Armstrong J, Periasamy Karuppiah A . Notes from the Field: HIV Infection Investigation in a Rural Area - West Virginia, 2017. MMWR Morb Mortal Wkly Rep. 2018; 67(8):257-258. PMC: 5861700. DOI: 10.15585/mmwr.mm6708a6. View

Sorensen J, Copeland A . Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000; 59(1):17-31. DOI: 10.1016/s0376-8716(99)00104-0. View

Woody G, Bruce D, Korthuis P, Chhatre S, Poole S, Hillhouse M . HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014; 66(3):288-93. PMC: 4146664. DOI: 10.1097/QAI.0000000000000165. View

Godersky M, Klein J, Merrill J, Blalock K, Saxon A, Samet J . Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. J Addict Med. 2020; 14(4):319-325. PMC: 7358111. DOI: 10.1097/ADM.0000000000000608. View

Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K . Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015; 110(8):1330-9. PMC: 4503496. DOI: 10.1111/add.12970. View

Karki P, Shrestha R, Huedo-Medina T, Copenhaver M . The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evid Based Med Public Health. 2016; 2. PMC: 4824190. View

Wang M, Mao W, Zhang L, Jiang B, Xiao Y, Jia Y . Methadone maintenance therapy and HIV counseling and testing are associated with lower frequency of risky behaviors among injection drug users in China. Subst Use Misuse. 2014; 50(1):15-23. DOI: 10.3109/10826084.2014.957768. View

Serpelloni G, Carrieri M, Rezza G, Morganti S, Gomma M, Binkin N . Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care. 1994; 6(2):215-20. DOI: 10.1080/09540129408258632. View

Roux P, Carrieri M, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P . Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009; 49(9):1433-40. DOI: 10.1086/630209. View

10.

Ball J, Lange W, Myers C, Friedman S . Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988; 29(3):214-26. View

11.

Peters P, Pontones P, Hoover K, Patel M, Galang R, Shields J . HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016; 375(3):229-39. DOI: 10.1056/NEJMoa1515195. View

12.

Cranston K, Alpren C, John B, Dawson E, Roosevelt K, Burrage A . Notes from the Field: HIV Diagnoses Among Persons Who Inject Drugs - Northeastern Massachusetts, 2015-2018. MMWR Morb Mortal Wkly Rep. 2019; 68(10):253-254. PMC: 6421964. DOI: 10.15585/mmwr.mm6810a6. View

13.

Novick D, Joseph H, Croxson T, Salsitz E, Wang G, Richman B . Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990; 150(1):97-9. View

14.

Golden M, Lechtenberg R, Glick S, Dombrowski J, Duchin J, Reuer J . Outbreak of Human Immunodeficiency Virus Infection Among Heterosexual Persons Who Are Living Homeless and Inject Drugs - Seattle, Washington, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(15):344-349. PMC: 6476056. DOI: 10.15585/mmwr.mm6815a2. View

15.

Spire B, Lucas G, Carrieri M . Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007; 18(4):262-70. DOI: 10.1016/j.drugpo.2006.12.014. View

16.

Altice F, Bruce R, Lucas G, Lum P, Korthuis P, Flanigan T . HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011; 56 Suppl 1:S22-32. PMC: 3263431. DOI: 10.1097/QAI.0b013e318209751e. View

17.

Samet J, Botticelli M, Bharel M . Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment. N Engl J Med. 2018; 379(1):7-8. DOI: 10.1056/NEJMp1803982. View

18.

Metzger D, Woody G, OBrien C . Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr. 2010; 55 Suppl 1:S32-6. PMC: 3155766. DOI: 10.1097/QAI.0b013e3181f9c10b. View

19.

Chen W, Xia Y, Hong Y, Hall B, Ling L . Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective study. Harm Reduct J. 2013; 10:23. PMC: 3853934. DOI: 10.1186/1477-7517-10-23. View

20.

MacArthur G, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J . Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012; 345:e5945. PMC: 3489107. DOI: 10.1136/bmj.e5945. View